These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 4049780)

  • 21. [Fibrinolytic activity of acyl-urokinase].
    Stürzebecher J; Kroneck I; Klöcking HP
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):137-43. PubMed ID: 2427394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug preparations of immobilized enzymes with enhanced affinity for the site of action].
    Torchilin VP; Maksimenko AV; Tishchenko EG; Papisov MI; Smirnov VN
    Antibiot Med Biotekhnol; 1986 Feb; 31(2):122-7. PubMed ID: 2421639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood coagulation changes during effective thrombolysis using urokinase and heparin.
    Schöffel G; Zimmermann R; Harenberg J; Mörl H
    Thromb Res; 1982 Jan 1-15; 25(1-2):11-21. PubMed ID: 6175040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urokinase immobilized on medical polymeric materials: fundamental and clinical studies.
    Ohshiro T; Kosaki G
    Artif Organs; 1980 Feb; 4(1):58-4. PubMed ID: 6989347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K; Vézina C
    J Med; 1974; 5(6):297-302. PubMed ID: 4528600
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiplatelet effects of urokinase and their clinical implications.
    Torr-Brown SR; Sobel BE
    Coron Artery Dis; 1996 Jan; 7(1):63-8. PubMed ID: 8773435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antithrombogenic effect of urokinase bound to the collagen surface with bifunctional antibodies].
    Stepanova IP; Tsybul'skaia MV; Domogatskiĭ SP
    Biull Eksp Biol Med; 1994 May; 117(5):504-7. PubMed ID: 9296703
    [No Abstract]   [Full Text] [Related]  

  • 31. The preparation of a urokinase-AT-III-PGE1-methyldopa complex, and its effects on platelet adhesion, coagulation times, protein adsorption, and fibrinolysis.
    Chandy T; Sharma CP
    Artif Organs; 1989 Jun; 13(3):229-37. PubMed ID: 2764762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin.
    Samama M; Castel M; Matsuo O; Hoylaerts M; Lijnen HR
    Thromb Haemost; 1982 Feb; 47(1):36-40. PubMed ID: 7041325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic urokinase: targeting of urokinase to fibrin clot.
    Yoshimoto T; Ohwada K; Takahashi K; Matsushima A; Saito Y; Inada Y
    Biochem Biophys Res Commun; 1988 Apr; 152(2):739-43. PubMed ID: 3365251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fibrinolytic properties and thrombolytic effect of a novel fibrinolytic enzyme from Streptomyces sp. Y405].
    Wang M; Wang J; Shao M; Wang M; Wang Y
    Yao Xue Xue Bao; 1998 Jul; 33(7):481-5. PubMed ID: 12016879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Islets surface modification prevents blood-mediated inflammatory responses.
    Teramura Y; Iwata H
    Bioconjug Chem; 2008 Jul; 19(7):1389-95. PubMed ID: 18533707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrapleural low-molecular-weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits.
    Idell S; Azghani A; Chen S; Koenig K; Mazar A; Kodandapani L; Bdeir K; Cines D; Kulikovskaya I; Allen T
    Exp Lung Res; 2007; 33(8-9):419-40. PubMed ID: 17994370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.
    Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C
    Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
    Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
    Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a recombinant chimeric plasminogen activator composed of Gly-Pro-Arg-Pro tetrapeptide and truncated urokinase-type plasminogen activator expressed in Escherichia coli.
    Hua ZC; Chen XC; Dong C; Zhu DX
    Biochem Biophys Res Commun; 1996 May; 222(2):576-83. PubMed ID: 8670247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.